RU2018113437A3 - - Google Patents
Download PDFInfo
- Publication number
- RU2018113437A3 RU2018113437A3 RU2018113437A RU2018113437A RU2018113437A3 RU 2018113437 A3 RU2018113437 A3 RU 2018113437A3 RU 2018113437 A RU2018113437 A RU 2018113437A RU 2018113437 A RU2018113437 A RU 2018113437A RU 2018113437 A3 RU2018113437 A3 RU 2018113437A3
- Authority
- RU
- Russia
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/5545—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having eight-membered rings not containing additional condensed or non-condensed nitrogen-containing 3-7 membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/18—Sulfonamides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4178—1,3-Diazoles not condensed 1,3-diazoles and containing further heterocyclic rings, e.g. pilocarpine, nitrofurantoin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/426—1,3-Thiazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
- A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
- A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
- A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
- A61K31/575—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of three or more carbon atoms, e.g. cholane, cholestane, ergosterol, sitosterol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/26—Glucagons
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/2031—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/70—Mechanisms involved in disease identification
- G01N2800/7052—Fibrosis
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Epidemiology (AREA)
- Engineering & Computer Science (AREA)
- Gastroenterology & Hepatology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Immunology (AREA)
- Endocrinology (AREA)
- Zoology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Steroid Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Investigating Or Analysing Biological Materials (AREA)
- Saccharide Compounds (AREA)
- Medicinal Preparation (AREA)
- Indole Compounds (AREA)
- Plural Heterocyclic Compounds (AREA)
- Other In-Based Heterocyclic Compounds (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Thiazole And Isothizaole Compounds (AREA)
- Pyrane Compounds (AREA)
- Pyrrole Compounds (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562219356P | 2015-09-16 | 2015-09-16 | |
US62/219,356 | 2015-09-16 | ||
PCT/US2016/022639 WO2017048322A1 (en) | 2015-09-16 | 2016-03-16 | Cenicriviroc combination therapy for the treatment of fibrosis |
Publications (2)
Publication Number | Publication Date |
---|---|
RU2018113437A3 true RU2018113437A3 (ru) | 2019-10-17 |
RU2018113437A RU2018113437A (ru) | 2019-10-17 |
Family
ID=58289631
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
RU2018113437A RU2018113437A (ru) | 2015-09-16 | 2016-03-16 | Комбинированная терапия с использованием ценикривирока для лечения фиброза |
Country Status (14)
Country | Link |
---|---|
US (2) | US20180360846A1 (ru) |
EP (1) | EP3349751A4 (ru) |
JP (1) | JP2018532720A (ru) |
KR (1) | KR20180088373A (ru) |
CN (1) | CN108289881A (ru) |
AU (1) | AU2016323468A1 (ru) |
BR (1) | BR112018005163A2 (ru) |
CA (1) | CA2998509A1 (ru) |
HK (1) | HK1258396A1 (ru) |
IL (1) | IL258002A (ru) |
MX (1) | MX2018003179A (ru) |
RU (1) | RU2018113437A (ru) |
SG (1) | SG10202002323UA (ru) |
WO (1) | WO2017048322A1 (ru) |
Families Citing this family (20)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2606499C (en) | 2005-05-26 | 2017-06-13 | Metabasis Therapeutics, Inc. | Thyromimetics for the treatment of fatty liver diseases |
WO2011140441A2 (en) | 2010-05-06 | 2011-11-10 | Children's Hospital Medical Center | Methods and systems for converting precursor cells into intestinal tissues through directed differentiation |
CA2949834A1 (en) | 2014-05-28 | 2015-12-03 | James Macormack Wells | Methods and systems for converting precursor cells into gastric tissues through directed differentiation |
WO2016061464A1 (en) | 2014-10-17 | 2016-04-21 | Children's Hospital Center, D/B/A Cincinnati Children's Hospital Medical Center | In vivo model of human small intetine using pluripotent stem cells and methods of making and using same |
EP3452578B1 (en) | 2016-05-05 | 2022-08-10 | Children's Hospital Medical Center | Methods for the in vitro manufacture of gastric fundus tissue and compositions related to same |
US20200056157A1 (en) | 2016-11-04 | 2020-02-20 | Children's Hospital Medical Center | Liver organoid disease models and methods of making and using same |
KR20190104524A (ko) | 2016-11-21 | 2019-09-10 | 바이킹 테라퓨틱스 인코포레이티드 | 당원축적질환의 치료 방법 |
AU2017373767B2 (en) | 2016-12-05 | 2021-09-16 | Children's Hospital Medical Center | Colonic organoids and methods of making and using same |
TW201828989A (zh) * | 2016-12-28 | 2018-08-16 | 華濤 劉 | 用於非酒精性脂性肝炎(nash)及肝纖維化之組合療法 |
JP2020510651A (ja) * | 2017-02-24 | 2020-04-09 | ジェンフィGenfit | 併用療法のための医薬組成物 |
BR112019025659A2 (pt) | 2017-06-05 | 2020-08-25 | Viking Therapeutics, Inc. | composições para o tratamento de fibrose |
CN109806386A (zh) * | 2017-11-20 | 2019-05-28 | 江苏恒瑞医药股份有限公司 | Fxr激动剂与glp-1类似物的药物组合物和用途 |
JP2021518403A (ja) | 2018-03-22 | 2021-08-02 | バイキング・セラピューティクス・インコーポレイテッド | 化合物の結晶形態及び化合物の結晶形態を生成する方法 |
US11813277B2 (en) | 2018-06-27 | 2023-11-14 | The Regents Of The University Of California | Methods and agents for modulating inflammation |
CN113677336B (zh) * | 2019-04-10 | 2024-04-30 | 基恩菲特公司 | 包含式(i)化合物和glp-1受体激动剂的组合疗法 |
CN110559297B (zh) * | 2019-09-09 | 2023-03-17 | 中山大学 | 咪唑并吡啶类化合物在制备抗黄病毒属病毒感染试剂或药物中的应用 |
US20230183221A1 (en) * | 2020-05-22 | 2023-06-15 | Medshine Discovery Inc. | Pyridine derivative and application thereof |
CN114028377A (zh) * | 2021-11-29 | 2022-02-11 | 中国农业大学 | 咖啡醇的医药新用途 |
AU2022433642A1 (en) * | 2022-01-14 | 2024-05-09 | Dimerix Bioscience Pty Ltd | Compositions comprising a chemokine receptor pathway inhibitor |
CN115414363B (zh) * | 2022-10-08 | 2023-07-07 | 湖南师范大学 | 抗肝癌组合物和苯乙双胍在制备抗肝癌药物增敏剂的应用 |
Family Cites Families (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1696910A4 (en) * | 2003-09-26 | 2009-12-09 | Smithkline Beecham Corp | COMPOSITIONS AND METHOD FOR THE TREATMENT OF FIBROSIS |
CN103476410B (zh) * | 2011-01-11 | 2020-02-21 | 戴麦里克斯生物科学有限公司 | 联合疗法 |
BR112015028644A2 (pt) * | 2013-05-15 | 2017-07-25 | Tobira Therapeutics Inc | composições de cenicriviroc e métodos de criação e uso do mesmo |
TW201610168A (zh) * | 2013-12-02 | 2016-03-16 | 安可美德藥物股份有限公司 | 與Wnt途徑抑制劑有關之預測性生物標記之鑑別 |
CN106488769A (zh) * | 2014-03-21 | 2017-03-08 | 妥必徕疗治公司 | 用于治疗纤维化的赛尼克韦罗 |
WO2015164733A1 (en) * | 2014-04-25 | 2015-10-29 | The Johns Hopkins University | Compositions comprising cyclodextrin incorporated collagen matrices for use in biomedical applications |
EP3191100A4 (en) * | 2014-09-12 | 2018-05-30 | Tobira Therapeutics, Inc. | Cenicriviroc combination therapy for the treatment of fibrosis |
-
2016
- 2016-03-16 MX MX2018003179A patent/MX2018003179A/es unknown
- 2016-03-16 EP EP16846982.3A patent/EP3349751A4/en not_active Withdrawn
- 2016-03-16 SG SG10202002323UA patent/SG10202002323UA/en unknown
- 2016-03-16 BR BR112018005163A patent/BR112018005163A2/pt not_active Application Discontinuation
- 2016-03-16 KR KR1020187010621A patent/KR20180088373A/ko not_active Application Discontinuation
- 2016-03-16 WO PCT/US2016/022639 patent/WO2017048322A1/en active Application Filing
- 2016-03-16 CN CN201680063405.7A patent/CN108289881A/zh active Pending
- 2016-03-16 JP JP2018513847A patent/JP2018532720A/ja active Pending
- 2016-03-16 RU RU2018113437A patent/RU2018113437A/ru unknown
- 2016-03-16 US US15/759,886 patent/US20180360846A1/en not_active Abandoned
- 2016-03-16 AU AU2016323468A patent/AU2016323468A1/en not_active Abandoned
- 2016-03-16 CA CA2998509A patent/CA2998509A1/en not_active Abandoned
-
2018
- 2018-03-11 IL IL258002A patent/IL258002A/en unknown
-
2019
- 2019-01-17 HK HK19100803.6A patent/HK1258396A1/zh unknown
-
2020
- 2020-02-27 US US16/803,931 patent/US20200268768A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
MX2018003179A (es) | 2018-08-21 |
CN108289881A (zh) | 2018-07-17 |
EP3349751A1 (en) | 2018-07-25 |
HK1258396A1 (zh) | 2019-11-08 |
EP3349751A4 (en) | 2019-05-22 |
US20200268768A1 (en) | 2020-08-27 |
AU2016323468A1 (en) | 2018-04-26 |
RU2018113437A (ru) | 2019-10-17 |
SG10202002323UA (en) | 2020-05-28 |
IL258002A (en) | 2018-05-31 |
US20180360846A1 (en) | 2018-12-20 |
BR112018005163A2 (pt) | 2018-10-09 |
CA2998509A1 (en) | 2017-03-23 |
JP2018532720A (ja) | 2018-11-08 |
KR20180088373A (ko) | 2018-08-03 |
WO2017048322A1 (en) | 2017-03-23 |